Ciprofloxacin for 2 or 4 weeks in the treatment of febrile urinary tract infection in men: A randomized trial with a 1 year follow-up

Scandinavian Journal of Infectious Diseases

Volumn 35, Issue 1, 2003, Pages 34-39

  Ulleryd, Peter ^a   Sandberg, Torsten ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BACTERIOLOGY; BACTERIURIA; BALANITIS; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; FEVER; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MALE; MUSCLE WEAKNESS; ORGAN SIZE; PROSPECTIVE STUDY; PROSTATE DISEASE; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RECURRENT INFECTION; STATISTICAL ANALYSIS; TREATMENT OUTCOME; URINARY TRACT INFECTION; VERTIGO;

ADMINISTRATION, ORAL; ADULT; AGED; CIPROFLOXACIN; CONFIDENCE INTERVALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEVER; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROBABILITY; PROSPECTIVE STUDIES; REFERENCE VALUES; SEVERITY OF ILLNESS INDEX; SINGLE-BLIND METHOD; STATISTICS, NONPARAMETRIC; TIME FACTORS; TREATMENT OUTCOME; URINALYSIS; URINARY TRACT INFECTIONS;

EID: 0037226472     PISSN: 00365548     EISSN: None     Source Type: Journal    
DOI: 10.1080/0036554021000026988     Document Type: Article

References (24)

1. Warren JW, Abrutyn E, Hebel JR, Johnson JR, Schaeffer AJ, Stamm WE. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Clin Infect Dis 1999; 29: 745-58.
2. Norrby SR. Short-term treatment of uncomplicated lower urinary tract infections in women. Rev Infect Dis 1990; 12: 458-67.
3. Gleckman R, Crowley M, Natsios GA. Therapy of recurrent invasive urinary-tract infections of men. N Engl J Med 1979; 301: 878-80.
4. Smith JW, Jones SR, Reed WP, Tice AD, Deupree RH, Kaijser B. Recurrent urinary tract infections in men. Characteristics and response to therapy. Ann Intern Med 1979; 91: 544-8.
5. Sabbaj J, Hoagland VL, Cook T. Norfloxacin versus co-trimoxazole in the treatment of recurring urinary tract infections in men. Scand J Infect Dis 1986; 48 (Suppl): S48-53.
6. Meares EM, Stamey TA. Bacteriologic localization patterns in bacterial prostatitis and urethritis. Invest Urol 1968; 5: 492-518.
7. Lipsky BA. Urinary tract infections in men. Epidemiology, pathophysiology, diagnosis, and treatment. Ann Intern Med 1989; 110: 138-50.
8. Pfau A. The treatment of chronic bacterial prostatitis: principles and management. In: Weidner W, Madsen PO, Schiefer HG, eds. Prostatitis. Etiopathology, diagnosis, and therapy. Berlin: Springer, 1994: 158-74.
9. Ulleryd P, Zackrisson B, Aus G, Bergdahl S, Hugosson J, Sandberg T. Prostatic involvement in men with febrile urinary tract infection as measured by serum prostate-specific antigen and transrectal ultrasonography. BJU Int 1999; 84: 470-4.
10. Naber KG. The role of quinolones in the treatment of chronic bacterial prostatitis. In: Weidner W, Madsen PO, Schiefer HG, eds. Prostatitis. Etiopathology, diagnosis, and therapy. Berlin: Springer, 1994: 175-90.
11. Bjerklund Johansen TE, Grüneberg RN, Guibert J, Hofstetter A, Lobel B, Naber KG, et al. The role of antibiotics in the treatment of chronic prostatitis: a consensus statement. Eur Urol 1998; 34: 457-66.
12. Rubin RH, Shapiro ED, Andriole VT, Davis RJ, Stamm WE. Evaluation of new anti-infective drugs for the treatment of urinary tract infection. Clin Infect Dis 1992; 15 (Suppl): S216-27.
13. Olsson-Liljequist B, Larsson P, Walder M, Miörner H. Antimicrobial susceptibility testing in Sweden. III. Methodology for susceptibility testing. Scand J Infect Dis 1997; 105 (Suppl): S13-23.
14. Ørskov F, Ørskov I. Serotyping of Escherichia coli. In: Bergan T, ed. Methods in microbiology. London: Academic Press, 1984: 43-112.
15. Sandberg T, Englund G, Lincoln K, Nilsson LG. Randomised double-blind study of norfloxacin and cefadroxil in the treatment of acute pyelonephritis. Eur J Clin Microbiol Infect Dis 1990; 9: 317-23.
16. Cronberg S, Banke S, Bergman B, Boman H, Eilard T, Elbel E, et al. Fewer bacterial relapses after oral treatment with norfloxacin than with ceftibuten in acute pyelonephritis initially treated with intravenous cefuroxime. Scand J Infect Dis 2001; 33: 339-43.
17. Ulleryd P, Zackrisson B, Aus G, Bergdahl S, Hugosson J, Sandberg T. Selective urological evaluation in men with febrile urinary tract infection. BJU Int 2001; 88: 15-20.
18. Warren JW. Clinical presentations and epidemiology of urinary tract infections. In: Mobley HLT, Warren JW, eds. Urinary tract infections: molecular pathogenesis and clinical management. Washington, DC: ASM Press, 1996: 3-27.
19. Sandberg T, Stokland E, Brolin I, Lidin-Janson G, Svanborg-Edén C. Selective use of excretory urography in women with acute pyelonephritis. J Urol 1989; 141: 1290-4.
20. Kärkkäinen U-M, Ikäheimo R, Katila M-L, Siitonen A. Recurrence of urinary tract infections in adult patients with community-acquired pyelonephritis caused by E. coli: a 1-year follow-up. Scand J Infect Dis 2000; 32: 495-9.
21. Lipsky BA. Prostatitis and urinary tract infection in men: what's new; what's true? Am J Med 1999; 106: 327-34.
22. Nickel JC. Prostatitis. In: Mulholland SG, ed. Antibiotic therapy in urology. Philadelphia, PA: Lippincott-Raven, 1996: 57-69.
23. Choong S, Whitfield H. Biofilms and their role in infections in urology. BJU Int 2000; 86: 935-41.
24. Naber KG, Busch W, Focht J, German Prostatitis Study Group. Ciprofloxacin in the treatment of chronic bacterial prostatitis: a prospective, non-comparative multicentre clinical trial with long-term follow-up. Int J Antimicrob Ag 2000; 14: 143-9.